




The relative strengths and weaknesses of Endocyte INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endocyte INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 153% points. The greatest weakness of Endocyte INC is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 361%, being 109% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	98,573
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,546
Liabilities, Non-Current	0
Other Assets	7.1
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	732
Other Net Income	1,112
Other Revenues	0
Property and Equipment	2,182
Research and Development	42,406
Selling, General and Administrative Expense	13,770

Output Variable	Value in 1000 USD
Assets	100,762
Liabilities	5,278
Expenses	56,176
Revenues	0
Stockholders Equity	95,484
Net Income	-55,064
Comprehensive Net Income	-55,076
BaseVar	81,676
ECR before LimitedLiability	289%
Economic Capital Ratio	361%